Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Shonda A. Foster"'
Autor:
Janet H. Ford, Shonda A. Foster, Russell M. Nichols, Antje Tockhorn-Heidenreich, Wenyu Ye, James Jackson, Sarah Cotton
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-11 (2020)
Abstract Background Migraine has a severe impact on health-related quality of life (HRQoL) affecting physical, emotional, and social aspects of daily living of an individual. Preventive treatment has been demonstrated to improve HRQoL by reducing the
Externí odkaz:
https://doaj.org/article/2b407cae4b9a471d8b9f78798fcd6495
Autor:
Yan Dong, Margarita Sanchez del Rio, Leslie Citrome, Antje Tockhorn-Heidenreich, Virginia L. Stauffer, Russell M Nichols, Shonda A. Foster
Publikováno v:
Advances in Therapy
Introduction Subcutaneous galcanezumab was an effective, well-tolerated preventive treatment for adults with episodic (EM) or chronic migraine (CM) in 4 phase 3 randomized controlled trials: EVOLVE-1, EVOLVE-2, REGAIN, and CONQUER. Number needed to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88c66d6cfcd505331de16056f27189ec
http://europepmc.org/articles/PMC8342379
http://europepmc.org/articles/PMC8342379
Autor:
Joshua A. Tobin, Shivang Joshi, Janet H. Ford, Russell M. Nichols, Shonda A. Foster, Dustin Ruff, Holland C. Detke, Sheena K. Aurora
Publikováno v:
Journal of medical economics. 25(1)
To analyze secondary objectives of the REGAIN study related to acute headache medication use and healthcare resource utilization (HCRU) in patients with chronic migraine treated with galcanezumab, a monoclonal antibody to calcitonin gene-related pept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aab3fef46bc2e3a284c7fc4c45307b9
https://pubmed.ncbi.nlm.nih.gov/35971655
https://pubmed.ncbi.nlm.nih.gov/35971655
Autor:
Chi-Chang Chen, Shonda A. Foster, Wenyu Ye, Catherine B McGuiness, Timothy R Smith, Shivang Joshi, Rolin L Wade, Oksana Mason, Paula C. Morrow, Yao Ding
Publikováno v:
Journal of Medical Economics. 23:1356-1364
To evaluate the prevalence and risk factors of migraine progression and to assess the incremental burden of migraine progression on healthcare systems.Adult patients were required to have a migraine diagnosis in IQVIA's US adjudicated claims database
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b18ad5aecae5d15496efa7d0284950
https://doi.org/10.1080/13696998.2020.1814790
https://doi.org/10.1080/13696998.2020.1814790
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:46-59
Migraine is a common and disabling neurological disease associated with substantial economic burden. Among patients with migraine, it is unknown if cost differences exist when preventive migraine medication (PMM) switches occur.To understand the cost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25b3d1760caef48ca475eaa53ccf91f
https://doi.org/10.18553/jmcp.2018.18058
https://doi.org/10.18553/jmcp.2018.18058
Autor:
Wenyu Ye, Karen Samaan, Dena H. Jaffe, Oksana Mason, John C. Rowland, Shonda A. Foster, Bridget L. Balkaran, M. Janelle Cambron-Mellott
To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. This retrospective study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8588ae9ce0db5cfc9ccee610b78e900b
This study compared all-cause direct cost and healthcare resource utilization (HCRU) among preventive migraine medication (PMM)-naïve patients and patients with up to 3 PMM category switches before initiating calcitonin gene-related peptide (CGRP) m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7337578d76e6408f59d3ebc4f473b79
Autor:
Russell M Nichols, James Jackson, Shonda A. Foster, Janet H. Ford, Sarah Cotton, Wenyu Ye, Antje Tockhorn-Heidenreich
Publikováno v:
Journal of Patient-Reported Outcomes
Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-11 (2020)
Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-11 (2020)
Background Migraine has a severe impact on health-related quality of life (HRQoL) affecting physical, emotional, and social aspects of daily living of an individual. Preventive treatment has been demonstrated to improve HRQoL by reducing the frequenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::632d57878ce77e5454a1f56ec5ad9db9
http://europepmc.org/articles/PMC7338330
http://europepmc.org/articles/PMC7338330
Autor:
Brian S. Comer, April W. Armstrong, Orin Goldblum, William N Malatestinic, Shonda A. Foster, Russel Burge, Chen-Yen Lin
Publikováno v:
BMC Dermatology, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Dermatology
BMC Dermatology
Background Little is known regarding real-world health outcomes data among US psoriasis patients, but electronic health records (EHR) that collect structured data at point-of-care may provide opportunities to investigate real-world health outcomes am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bdd2d1494de3311e719c484c69a3fbd
http://link.springer.com/article/10.1186/s12895-018-0072-2
http://link.springer.com/article/10.1186/s12895-018-0072-2
Publikováno v:
Journal of medical economics. 22(9)
Aim: Within a treated migraine population, to evaluate if the sub-group meeting criteria for high disease-specific total costs is significantly different to the sub-group with medium and/or...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::496a9cc40aaabf4e6bc88cd456e4438d
https://pubmed.ncbi.nlm.nih.gov/30977712
https://pubmed.ncbi.nlm.nih.gov/30977712